Last reviewed · How we verify
SMS995
At a glance
| Generic name | SMS995 |
|---|---|
| Also known as | Octreotide, Sandostatin |
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut (PHASE3)
- Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly (PHASE4)
- Octreotide Efficacy and Safety in First-line Acromegalic Patients (PHASE4)
- Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas (PHASE4)
- Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly (PHASE3)
- Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SMS995 CI brief — competitive landscape report
- SMS995 updates RSS · CI watch RSS
- Novartis portfolio CI